회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 화학/신소재 > 화학
Investigation Report on China Esomeprazole Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-05
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

Digestive system disease is one of frequently-occurring diseases. According to statistics of WHO, there are at least 250 million digestive tract patients, mainly suffering from canker.
Inhibition of gastric acid secretion is the key treatment method for peptic ulcer, duodenal ulcer and gastroesophageal reflux disease. The H+ / K+ ATP enzyme in gastric parietal cells can reduce gastric acid secretion. By inhibiting the functioning of this transporter, the drug prevents formation of gastric acid. Proton pump inhibitor, namely H+/K+-ATP enzyme, inhibits the avidity of H+/K+-ATP enzyme to block gastric acid secretion caused by any stimulation

Esomeprazole is a proton pump inhibitor that appeared on the market in 2000. It becomes popular in the market because of high bioavailability, effective and lasting inhibition of gastric acid and low toxic and side effect. Total sales revenue of Nexium (trade name of esomeprazole produced by Astra Zeneca) since it was launched is over tens of billions dollars, making it one of the most important products from Astra Zeneca. Patent No. 94190335. 4 is the most crucial patent for Nexium which expires in May 2014. To avoid time-consuming and costly patent infringement lawsuits, Astra Zeneca announced in October 2011 that generic drug manufacturers with cooperation intention needed to pay royalty before producing esomeprazole generic drugs. Though generic drugs take part of Nexium's market, Astra Zeneca can recoup the loss by charging patent royalty.

Statistics shows that there are over 120 million people suffering from enterogastric diseases in China, which is the most in the world. Incidence of peptic ulcer is 10% while that of chronic gastritis is 30%.

Nexium produced by Astra Zeneca entered China in 2004. According to CRI's investigation in China market, the CAGR of sales revenue of esomeprazole outstepped 48% from 2005 to 2014. In 2014, the sales value in sample hospital exceeded CNY 80 million, which was spectacularly successful. By the end of 2014, Chinese market was absolutely dominated by products from Astra Zeneca.

Chongqing LUMMY Pharmaceutical Co., Ltd. applied for 4 new drug registrations with esomeprazole in 2010, which was approved in August 2013. It is estimated that market pattern of esomeprazole in China will change in 2015. In the short term Nexium produced by Astra Zeneca will still have an absolute advantage in the market, but its market share will decline in the long run.

Through this report, the readers can acquire the following information:
-Sales Price of Esomeprazole (Nexium) in China Hospital Market
-Major Esomeprazole Manufacturers in China
Patent Status of Esomeprazole in China
-Share of Esomeprazole in Different Dosage Forms in China Hospital Market
-Prospect of China Esomeprazole Market

The Following Enterprises and People Are Recommended to Purchase This Report:
-Manufacturers of Digestive System Diseases Medication
-Investors on China Digestive System Diseases Drug Market


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.